Thermo Fisher Scientific (NYSE:TMO) Stock Rating Upgraded by Jefferies Financial Group

Key Points

• Jefferies upgraded Thermo Fisher Scientific (TMO) to a "strong-buy," and MarketBeat shows a consensus Buy rating with a consensus price target of $625.55 (2 Strong Buy, 19 Buy, 2 Hold).
• TMO beat Q1 expectations with adjusted EPS of $5.44 (vs. ~$5.25 consensus) and revenue of $11.01B (+6.2% y/y), and management set FY2026 guidance of $24.64–$25.12 EPS.
• CEO Marc N. Casper sold 5,000 shares (~$2.56M) in March; insiders now own just 0.33% of the stock while institutional investors hold about 89.23%.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) was upgraded by equities researchers at Jefferies Financial Group to a "strong-buy" rating in a research note issued on Friday,Zacks.com reports.

Other analysts have also issued research reports about the stock. TD Cowen dropped their price target on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating for the company in a research note on Friday, January 30th. Evercore restated an "outperform" rating and issued a $650.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, January 5th. Robert W. Baird dropped their price target on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating for the company in a research note on Friday. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Saturday, February 28th. Finally, UBS Group restated a "neutral" rating and issued a $615.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of "Buy" and a consensus price target of $625.55.

Thermo Fisher Scientific Trading Up 0.6%

NYSE TMO opened at $469.27 on Friday. The company's fifty day simple moving average is $499.11 and its 200-day simple moving average is $549.45. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $643.99. The company has a current ratio of 1.53, a quick ratio of 1.53 and a debt-to-equity ratio of 0.77. The stock has a market cap of $174.39 billion, a P/E ratio of 25.80, a PEG ratio of 2.41 and a beta of 0.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts' consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion for the quarter, compared to analysts' expectations of $10.86 billion. During the same period in the previous year, the company posted $5.15 earnings per share. The business's revenue for the quarter was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts predict that Thermo Fisher Scientific will post 24.71 EPS for the current fiscal year.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,000 shares of the business's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer owned 123,925 shares in the company, valued at $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the transaction, the executive vice president owned 20,752 shares of the company's stock, valued at $11,230,982.40. This represents a 1.89% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.33% of the stock is owned by insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

Institutional investors have recently modified their holdings of the company. High Note Wealth LLC grew its position in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after acquiring an additional 29 shares during the last quarter. Swiss RE Ltd. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $28,000. Beacon Financial Strategies CORP bought a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $29,000. Olistico Wealth LLC bought a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $29,000. Finally, Birchwood Financial Partners Inc. bought a new position in shares of Thermo Fisher Scientific during the fourth quarter worth about $29,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q1 results beat expectations — Thermo Fisher reported $5.44 adjusted EPS vs. ~$5.25 consensus and revenue of $11.01B (up ~6.2% y/y), showing the company still delivered above-street top- and bottom-line results. Reuters: Thermo Fisher posts quarterly results beat
• Positive Sentiment: Full-year guidance updated — Management set FY2026 EPS guidance of $24.64–$25.12 and raised its outlook, which supports longer-term earnings visibility even if organic growth is uneven. Yahoo: Thermo Fisher Raises 2026 Outlook
• Neutral Sentiment: Analyst reactions mixed but generally constructive — Several firms kept buy/outperform ratings while trimming targets (Stifel: $700->$600; Robert W. Baird: $653->$639), signaling continued confidence in the company’s fundamentals despite the pullback. Benzinga / The Fly: PT cuts
• Neutral Sentiment: Analyst voices emphasize long-term opportunity — Some analysts (e.g., TD Cowen, William Blair) reiterated Buy ratings, pointing to core growth drivers and structural demand (biopharma services, lab products) that support recovery later in the year. TipRanks: Analyst commentary
• Negative Sentiment: Market punished the stock on weak underlying growth and mixed segments — Despite the beat, investors focused on muted organic growth in the core business and uneven segment performance, which triggered a sharp intraday decline and premarket weakness. Yahoo: Why TMO Stock Is Nosediving
• Negative Sentiment: Broader sector & market pressure amplified the move — The mixed report pressured peers (e.g., 10x Genomics) and coincided with a softer tape for health care/tech stocks, adding to downward momentum. Yahoo: Peer impact (10x Genomics)

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.